Posted by Michael Wonder on 20 Nov 2019
Generic drug approvals soar, but patients still go without
19 November 2019 - Brand name makers’ patent action limits release of the lower-price medicines, hindering cost-control efforts.
Record numbers of generic drugs for cancer, heart ailments and other conditions have received U.S. approval in recent years, raising hopes that the new competition would reduce high drug costs. But many of the lower-price medicines haven’t hit the market, a Wall Street Journal review found.
The result: many patients are forced to take high-price medicines, and a widely touted remedy for reining in drug costs has failed to live up to its promise.
